|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression |
BEFREE |
Breast cancer cells underwent a series of molecular changes as they progressed from primary tumours to bone metastasis including altered expression of IL-1B, IL-1R1, S100A4, CTSK, SPP1 and RANK.
|
31783893 |
2019 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Thus inhibition of the RANKL-RANK pathway is a promising treatment for bone metastasis, and a human monoclonal anti-RANKL antibody, denosumab, has been used in the clinic.
|
30622830 |
2019 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
In light of the RANKL-RANK multi-task function, an antibody targeting this pathway, denosumab, is now commonly used in the therapy of bone loss diseases including chronic inflammatory bone disorders and osteolytic bone metastases; furthermore, preclinical data support the therapeutic application of denosumab in the framework of a broader spectrum of tumors.
|
30984193 |
2019 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis.
|
31014505 |
2019 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression |
BEFREE |
The mRNA expression of RANK was highest in tumour tissue from patients with bone metastases (p < 0.001) as compared to BPH or locally confined tumours, also shown in clinical subgroups distinguished by Gleason Score (< 7 or ≥ 7, p = 0.028) or PSA level (< 10 or ≥ 10 µg/l, p = 0.004).
|
29204705 |
2018 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Receptor activator of nuclear factor-κB (RANK) and the RANK ligand (RANKL) were initially described in the context of T cell-dendritic cell interactions; however, the discovery of an obligate role of RANK signalling in osteoclastogenesis led to the development of the anti-RANKL antibody denosumab for antiresorptive indications, including bone metastases.
|
30232468 |
2018 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
In addition, this chapter provides an update on the role receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) play on breast cancer development and their subsequent influence during the homing and establishment of breast cancer-associated bone metastases.
|
29282685 |
2017 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
RANK is increased in HR negative and basal BC, and correlates with worse RFS and risk of BM.
|
28577080 |
2017 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
These results suggest that the mechanisms of RANK/RANKL signaling are involved in the ADT-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
|
28373003 |
2017 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation |
BEFREE |
The purpose of this study was to investigate whether PAP effects on OB bone metastases are mediated by autocrine and/or paracrine alterations in the receptor activator of nuclear factor κ-B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system.
|
27783536 |
2016 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation |
BEFREE |
Our analysis shows that RANK SNP rs34945627 has a high allelic frequency in patients with BC and BM, and is associated with decreased DFS and OS.
|
27191503 |
2016 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Bone homeostasis critically relies on the RANKL-RANK-OPG axis which can be targeted by the fully human monoclonal antibody denosumab in conditions with increased bone resporption such as bone metastases.
|
25138051 |
2014 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression |
BEFREE |
Expression of RANK ligand (RANKL) and insulin-like growth factor-I receptor (IGF-IR), key mediators of bone metastases, were elevated in SBC-5 as compared with SBC-3 cells.
|
23966614 |
2014 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
AlteredExpression |
BEFREE |
Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
|
23516466 |
2013 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
The aim of this study was to identify additional therapeutic targets that can be combined with OPG/RANKL/RANK pathway inhibition in the treatment of prostate cancer bone metastasis.
|
23708710 |
2013 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Although the mechanisms of the development of BM are not completely clear, it is now well understood that the Receptor Activator of Nuclear factor Kappa-B-/Ligand (RANK/RANKL)/osteoprotegerin (OPG) pathway plays a relevant role.
|
23336103 |
2013 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Combining RANK-Fc with rhApo2L/TRAIL was superior to either rhApo2L/TRAIL or RANK-Fc alone at reducing skeletal tumor burden in the bone metastasis model.
|
20150760 |
2010 |
|
TNFRSF11A
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker |
BEFREE |
Enhanced production of receptor activator of nuclear factor-kappaB ligand (RANKL) and its binding to RANK on the osteoclasts have been associated with osteolysis in breast cancer bone metastasis.
|
18388919 |
2008 |